Eaton Vance Management increased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 24.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,875,168 shares of the medical research company’s stock after buying an additional 372,803 shares during the period. Eaton Vance Management owned 0.25% of Amgen worth $285,307,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Oakworth Capital Inc. raised its stake in shares of Amgen by 16.6% in the second quarter. Oakworth Capital Inc. now owns 701 shares of the medical research company’s stock worth $111,000 after buying an additional 100 shares in the last quarter. Integrated Wealth Management raised its stake in shares of Amgen by 0.3% in the second quarter. Integrated Wealth Management now owns 930 shares of the medical research company’s stock worth $141,000 after buying an additional 3 shares in the last quarter. Delta Asset Management LLC TN raised its stake in shares of Amgen by 9.1% in the second quarter. Delta Asset Management LLC TN now owns 1,020 shares of the medical research company’s stock worth $155,000 after buying an additional 85 shares in the last quarter. Capital Advisors Ltd. LLC raised its stake in shares of Amgen by 0.6% in the second quarter. Capital Advisors Ltd. LLC now owns 1,078 shares of the medical research company’s stock worth $164,000 after buying an additional 6 shares in the last quarter. Finally, Hanson & Doremus Investment Management raised its stake in shares of Amgen by 3.0% in the second quarter. Hanson & Doremus Investment Management now owns 1,191 shares of the medical research company’s stock worth $181,000 after buying an additional 35 shares in the last quarter. Hedge funds and other institutional investors own 79.15% of the company’s stock.

Amgen Inc. (NASDAQ:AMGN) traded down 0.62% on Wednesday, reaching $172.30. 946,202 shares of the company’s stock were exchanged. The company has a market cap of $128.94 billion, a PE ratio of 17.63 and a beta of 0.87. The firm’s 50 day moving average price is $171.98 and its 200 day moving average price is $159.67. Amgen Inc. has a 52-week low of $130.09 and a 52-week high of $176.64.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Wednesday, July 27th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.74 by $0.10. Amgen had a net margin of 33.07% and a return on equity of 29.30%. The company earned $5.69 billion during the quarter, compared to analysts’ expectations of $5.58 billion. During the same period last year, the company posted $2.57 EPS. Amgen’s revenue was up 5.9% on a year-over-year basis. On average, analysts expect that Amgen Inc. will post $11.36 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 8th. Investors of record on Wednesday, August 17th were given a dividend of $1.00 per share. The ex-dividend date of this dividend was Monday, August 15th. This represents a $4.00 dividend on an annualized basis and a yield of 2.31%. Amgen’s dividend payout ratio (DPR) is currently 40.90%.

A number of analysts have weighed in on the stock. Jefferies Group raised their target price on shares of Amgen from $187.00 to $198.00 and gave the company a “buy” rating in a research report on Thursday, July 28th. Zacks Investment Research upgraded shares of Amgen from a “hold” rating to a “buy” rating and set a $166.00 price target on the stock in a report on Wednesday, June 29th. Vetr upgraded shares of Amgen from a “hold” rating to a “buy” rating and set a $159.50 price target on the stock in a report on Monday, June 13th. Leerink Swann reiterated a “hold” rating on shares of Amgen in a report on Sunday, June 26th. Finally, Argus reiterated a “buy” rating and set a $195.00 price target (up previously from $185.00) on shares of Amgen in a report on Friday, August 5th. One analyst has rated the stock with a sell rating, nine have given a hold rating and thirteen have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $184.87.

In related news, VP Annette Louise Such sold 3,000 shares of Amgen stock in a transaction dated Tuesday, August 2nd. The shares were sold at an average price of $174.59, for a total transaction of $523,770.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.20% of the company’s stock.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).

5 Day Chart for NASDAQ:AMGN

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.